Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Guggenheim downgraded Novo Nordisk (NVO) to Neutral from Buy.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Key Takeways U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & ...